Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it reduces pain‑signal sensitisation, lowers the hypothalamic set‑point for temperature, and diminishes inflammatory swelling and redness.

The specific dose of Ibuprofen B. Braun is determined by the prescribing clinician based on the patient’s age, weight, clinical condition and therapeutic goals. Healthcare professionals follow local guidelines and product labeling to select an appropriate intravenous dose and infusion rate.

Safety data for intravenous ibuprofen in pregnancy are limited, and the product does not have a definitive pregnancy category. It should only be used when the potential benefit justifies the possible risk to the fetus. Breastfeeding mothers should consult a physician, as ibuprofen can be excreted in milk.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Both ibuprofen and ketorolac are NSAIDs that inhibit COX enzymes, but ketorolac is generally considered more potent for short‑term postoperative pain and carries a higher risk of renal and gastrointestinal adverse effects. Ibuprofen offers a broader therapeutic window and is often preferred when a balance between efficacy and safety is desired, especially in patients with moderate renal risk.

Ibuprofen B. Braun must be stored refrigerated at 2 °C to 8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. Before administration, inspect the vial for particulate matter and ensure it is at the appropriate temperature.

The product is given by intravenous infusion. It is typically diluted in a compatible IV fluid and administered over a period defined by the prescribing information, often 15–30 minutes. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy.

Serious risks include gastrointestinal bleeding or ulceration, acute renal impairment, severe hypersensitivity reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for signs of bleeding, changes in urine output, rash, or respiratory distress during and after infusion.

Ibuprofen B. Braun is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and in those who have experienced a previous severe reaction to an intravenous NSAID. Caution is also advised in patients with uncontrolled hypertension or heart failure.